Skip to Content
  • Revenues ($M)
    $32,639
  • Revenue Percent Change
    31.1%
  • Profits ($M)
    $18,108
  • Profits Percent Change
    49.6%
  • Assets ($M)
    $51,839
  • Employees
    8,000
  • Market Value — as of March 31, 2016 ($M)
    $124,437
  • Previous Rank
    118
  • Morning Consult Brand Index
    D

The California-based biotech continued its rocket-like ascent in 2015–just two years ago it ranked No. 250 on the 500–due to booming sales of its breakthrough Hepatitis C medications. Those drugs–Sovaldi and Harvoni–which cost a fortune, but also cure a chronic, devastating disease, sparked a national debate on drug pricing. They also drove Gilead’s bottom and top lines in 2015–revenues and profits jumped 31% and 50%, respectively. John Milligan, Gilead’s new CEO faces rockier road in 2016: the competition is stiffer and IP challenges and pricing pressures loom.

41319CFF-E47E-4BA5-B1B8-ECA4D480B0DFCreated with sketchtool.62900797-6A09-46DF-8323-A45758A81292Created with sketchtool.Looking for leads, investment insights, or competitive intelligence?Buy Now

Company Info

CEO
John F. Milligan
Sector
Health Care
Industry
Pharmaceuticals
HQ Location
Foster City, CA
Websitehttp://www.gilead.com
Years on Fortune 500 List8
Employees8,000

Key Financials (last fiscal year)

$ millions% change
Revenues ($M)$32,63931.1%
Profits ($M)$18,10849.6%
Assets ($M)$51,839-
Total Stockholder Equity ($M)$18,534-
Market Value — as of March 31, 2016 ($M)$124,437-

Profit Ratios

Profit as % of Revenues55.5%
Profits as % of Assets34.9%
Profits as % of Stockholder Equity97.7%

Earnings Per Share (Last Fiscal Year)

Earnings Per Share ($)11.91
EPS % Change (from 2014)62%
EPS % Change (5 year annual rate)48.3%
EPS % Change (10 year annual rate)39.4%

Total Return

Total Return to Investors (2015)8.7%
Total Return to Investors (5 year, annualized)41.4%
Total Return to Investors (10 year, annualized)22.8%